SCHEMBL2227263

SCHEMBL2227263

CC(=O)c1[nH]c2ccccc2c1C=O

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
MAPT P10636 3/20 0.43
AHR P35869 3/20 0.43
LMNA P02545 1/20 0.43
GFER P55789 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAP2 P11137 1/20 0.42
GAA P10253 1/20 0.42
PBRM1 Q86U86 1/20 0.42
GSK3B P49841 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954980 0.84 KDM4E (0.57) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL5008079 0.84 KDM4E (0.57) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL1253813 0.82 EGFR (0.50) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL2800262 0.82 KDM4E (0.57) KDM4EMEN1KMT2AALDH1A1HPGD
Benzene SCHEMBL28244199 0.81 MEN1 (0.58) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL29643083 0.79 GABRA1 (0.49) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL9215592 0.79 GABRA1 (0.49) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL3198815 0.79 ALOX15 (0.68) KDM4EMEN1KMT2AALDH1A1HPGD
Acetic Acid SCHEMBL28679441 0.78 MAPT (0.60) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL10704376 0.77 ALDH1A1 (0.61) KDM4EMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0705279-A4 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORP (US) 1999-03-24 EP claimed
EP-0705279-A1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORPORATION (US) 1996-04-10 EP claimed
WO-2011091152-A1 INHIBITORS OF HEPATITIS C VIRUS INFECTION GASTAMINZA PABLO (US) 2011-07-28 WO disclosed
EP-2220026-A2 INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASE Sterix Limited (GB) 2010-08-25 EP disclosed
WO-2010014744-A1 INHIBITORS OF HEPATITIS C VIRUS INFECTION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-02-04 WO disclosed
WO-2009066072-A2 COMPOUND STERIX LIMITED (GB) 2009-05-28 WO disclosed
EP-1435962-A4 TREATMENT OF TYPE I DIABETES CELL PATHWAYS INC (US) 2009-04-15 EP disclosed
EP-1730049-A1 COSMETIC PORTION Henkel Kommanditgesellschaft auf Aktien (DE) 2006-12-13 EP disclosed
WO-2005085089-A1 COSMETIC PORTION HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2005-09-15 WO disclosed
EP-1528924-A1 MCH1R ANTAGONISTS Astrazeneca AB (SE) 2005-05-11 EP disclosed
EP-1435961-A4 TREATMENT FOR LUPUS ERYTHEMATOSUS CELL PATHWAYS INC (US) 2005-04-20 EP disclosed
WO-2004004726-A1 MCHIR ANTAGONISTS ASTRAZENECA AB (SE) 2004-01-15 WO disclosed
WO-2003017999-A1 TREATMENT OF SCLERODERMA CELL PATHWAYS, INC. (US) 2003-03-06 WO disclosed
WO-2003017765-A1 TREATMENT FOR CYSTIC FIBROSIS CELL PATHWAYS, INC. (US) 2003-03-06 WO disclosed
WO-2003017925-A2 TREATMENT OF TYPE I DIABETES CELL PATHWAYS, INC. (US) 2003-03-06 WO disclosed
WO-2003017926-A2 TREATMENT FOR LUPUS ERYTHEMATOSUS CELL PATHWAYS, INC. (US) 2003-03-06 WO disclosed
WO-2002067936-A1 METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE CELL PATHWAYS, INC. (US) 2002-09-06 WO disclosed
EP-1044187-A1 N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA OSI Pharmaceuticals, Inc. (US) 2000-10-18 EP disclosed
WO-1999031065-A1 N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA CELL PATHWAYS, INC. (US) 1999-06-24 WO disclosed
EP-0802902-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1997-10-29 EP disclosed